Itching To Succeed: UNION Buys LEO Pharma’s PDE4 Inhibitor Series

Danish Biotech Says PDE4 Inhibitor Series ‘Brings Pipeline Synergies’

Denmark-based UNION therapeutics has bought LEO Pharma’s PDE4 inhibitor compound series for use in developing treatments for psoriasis and atopic dermatitis.

Skin
UNION’s focus is immuno-dermatology, including psoriasis and atopic dermatitis. • Source: Shutterstock

Privately held UNION therapeutics A/S has bought LEO Pharma A/S's range of phosphodiesterase type 4 (PDE4) inhibitors, including the investigational compound orismilast, which the Danish biotech aims to develop as a treatment for psoriasis and as a topical therapy for atopic dermatitis.

Under the Danish duo’s pact, announced on 21 July, UNION will pay upfront, development and commercial milestones of up to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.